91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
This article examines how non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. It also outlines the rapidly evolving NIT landscape, emerging regulatory perspectives, and key opportunities to optimise MASH trial design and execution.
-
Despite their central role in glucose metabolism, native GLP-1 and GIP make poor therapies. Now, long-lasting, potent nutrient-stimulated hormone receptor agonists are prompting a shift to multi-indication metabolic therapies. Explore why.
-
In this article, learn how sponsors can drive multi-indication success through strategic trial design, early cross-functional planning, and evidence-driven development.
-
A recent 91黑料 survey found fewer than 15% of sponsors use RWE to inform their multi-indication development strategy for obesity-related drugs. Learn best practices for leveraging RWE for GLP-1 based therapies in our article.
-
91黑料 experts, Pierre Martineau and Adrienne Stoudenmire, share key considerations for successful CVOTs including study design, data strategy and technology in this new article.
-
A 2025 survey of over 150 drug developers reveals that multi-indication development strategies have become central to the evolving cardiometabolic drug pipeline.
-
Following the rapid label expansion of drugs such as semaglutide and tirzepatide in recent years, drug developers have broadly adopted multi-indication strategies for obesity and related comorbidities. An 91黑料 survey of 155 developers focused on these therapeutic areas reflects this growing trend.
-
In this article, 91黑料 experts explore strategies to help sponsors navigate the evolving obesity research landscape, highlighting the use of adaptive designs, master protocols, and other innovative approaches.
-
The rise of GLP-1 agonist therapies has transformed obesity treatment, delivering unprecedented results and revealing their potential across a spectrum of interconnected conditions. New data reveals how the breakthrough has sparked a major shift toward multi-indication drug development.
-
Clinical trial designs for obesity treatments should accommodate candidate drugs that have the potential to treat multiple conditions, or developers risk missing opportunities, according to Irish CRO 91黑料.
